1. Mortimer, EA Jr.. Pertussis. In: Evans, AS, Brachman, PS. Bacterial Infections of Humans, 3rd edn.New York and London: Plenum Medical Book Co., 1998, pp. 529–543.
2. Hewlett, EL, Halperin, SA. Serological correlates of immunity to Bordetella pertussis. Vaccine 1998; 16: 1899–1900.
3. Locht, C, Antoine, R, Jacob-Dubuisson, F. Bordetella pertussis, molecular pathogenesis under multiple aspects. Current Opinion in Microbiology 2001; 4: 82–89.
4. Tamura, M, et al. Subunit structure of islet-activating protein, pertussis toxin, in conformity with the A-B model. Biochemistry 1982; 21: 5516–5522.
5. Ladant, D, Ullmann, A. Bordetella pertussis adenylate cyclase: a toxin with multiple talents. Trends in Microbiology 1999; 7: 172–176.
6. Robbins, JB, Pittman, M. Bordetella. In: Davis, BD, Dulbecco, R, Eisen, HN, Ginsberg, HS eds. Microbiologia. Quarta ed. Zanichelli, 1998, pp. 638–641.
7. Cookson, BT, et al. Biological activities and chemical composition of purified tracheal cytotoxin of Bordetella pertussis. Infection and Immunity 1989; 57: 2223–2229.
8. Mills, KHG. Immunity to Bordetella pertussis. Microbes and Infection 2001; 3: 655–677.
9. Campins-Martì, M, et al. Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration. Vaccine 2001; 20: 641–646.
10. Wirsing von Konig, CH, Halperin, S, Riffelmann, M, Guiso, N. Pertussis of adults and infants. Lancet Infectious Diseases 2002; 2: 744–750.
11. Nelson, JD. The changing epidemiology of pertussis in young infants. The role of adults as reservoirs of infection. American Journal of Diseases of Children 1978; 132: 371–373.
12. Mink, CA, Sirota, NM, Nugent, S. Outbreak of pertussis in a fully immunized adolescent and adult population. Archives of Pediatrics & Adolescent Medicine 1994; 148: 153–157.
13. Wirsing von Konig, CH, et al. Pertussis in adults: frequency of transmission after household exposure. Lancet 1995; 346: 1326–1329. [Erratum in Lancet 1995; 346: 1502].
14. Senzilet, LD, et al. Sentinel Health Unit Surveillance System Pertussis Working Group. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clinical Infectious Diseases 2001; 32: 1691–1697.
15. Pastore Celentano, L, et al. , on behalf of the EUVAC-NET Group. Resurgence of pertussis in Europe. Pediatric Infectious Disease Journal 2005; 24: 761–765.
16. Edelman, K, et al. Immunity to pertussis 5 years after booster immunization during adolescence. Clinical Infectious Diseases 2007; 44: 1271–1277.
17. Preston, A. Bordetella pertussis: the intersection of genomics and pathobiology. Canadian Medical Association Journal 2005; 173: 55–62.
18. Storsaeter, J, et al. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998; 16: 1907–1916.
19. Cherry, JD, et al. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998; 16: 1901–1906.
20. Olin, P, et al. How to make sense of pertussis immunogenicity data. Clinical Infectious Diseases 2001; 33: S288–S291.
21. Rota, MC, et al. Prevalence of markers of exposure to Bordetella pertussis among Italian young adults. Clinical Infectious Diseases 1998; 26: 297–302.
22. Tran Minh, NN, et al. Cell-mediated immune responses to antigens of Bordetella pertussis and protection against pertussis in school children. Pediatric Infectious Disease Journal 1999; 18: 366–370.
23. Mattoo, S, Cherry, JD. Molecular pathogenesis, epidemiology and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clinical Microbiology Reviews 2005; 18: 326–382.
24. Giammanco, A, et al. European Seroepidemiology Network: standardisation of the assay results for pertussis. Vaccine 2003; 22: 112–120.
25. Pebody, RG, et al. The seroepidemiology of Bordetella pertussis infection in Western Europe. Epidemiology and Infection 2005; 133: 159–171.
26. Zuercher, AW, et al. Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine. Clinical and Experimental Immunology 2005; 143: 132–138.
27. Disis, ML, et al. Maximizing the retention of antigen specific lymphocyte function after cryopreservation. Journal of Immunological Methods 2006; 308: 13–18.
28. Binkin, NJ, et al. Epidemiology of pertussis in a developed country with low vaccination coverage: the Italian experience. Pediatric Infectious Disease Journal 1992; 11: 653–661.
29. Ciofi degli Atti, ML, et al. Do changes in policy affect vaccine coverage levels? Results of a national study to evaluate childhood vaccination coverage and reasons for missed vaccination in Italy. Vaccine 2004; 22: 4351–4357.
30. Rota, MC, et al. How increased pertussis vaccination coverage is changing the epidemiology of pertussis in Italy. Vaccine 2005; 23: 5299–5305.
31. Purdy, KW, et al. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clinical Infectious Diseases 2004; 39: 20–28.
32. Cherry, JD. The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics 2005; 115: 1422–1427.
33. Le, T, et al. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT study. Journal of Infectious Diseases 2004; 190: 535–544.
34. Giammanco, A, et al. Seroepidemiology of pertussis in Italy. Reviews of Infectious Diseases 1991; 13: 1216–1220.
35. De Melker, H, et al. Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. Journal of Clinical Microbiology 2000; 38: 800–806.
36. Polyzou, A, et al. Seroepidemiology of Bordetella pertussis immune responses in a healthy population in Northern Greece. Journal of Clinical Laboratory Analysis 2004; 18: 211–214.
37. Nardone, A, et al. Sero-epidemiology of Bordetella pertussis in England and Wales. Vaccine 2004; 22: 1314–1319.
38. Mills, KHG, et al. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infection and Immunity 1998; 66: 594–602.
39. Leef, M, et al. Protective immunity to Bordetella pertussis requires both B cells and CD4+ T cells for key functions other than specific antibody production. Journal of Experimental Medicine 2000; 191: 1841–1852.
40. Edelman, KJ, et al. Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine. Clinical Infectious Diseases 2004; 29: 179–185.
41. Forsyth, KD, et al. New pertussis vaccination strategies beyond infancy: recommendations by the Global Pertussis Initiative. Clinical Infectious Diseases 2004; 39: 1802–1809.
42. American Academy of Pediatrics. Committee on Infectious Diseases. Prevention of pertussis among adolescent: recommendations for use of Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine. Pediatrics. Published online 28 December 2005. doi: 10.1542/peds.2005-3038.
43. American Academy of Pediatrics. Committee on Infectious Diseases. Recommended childhood and adolescent immunization schedule – United States, 2006. Pediatrics 2006; 117: 239–240.
44. Bamberger, ES, et al. What is new in pertussis? European Journal of Pediatrics. Published online: 1 August 2007. doi: 10.1007/S00431-007-0548-2.
45. State Regional Conference. Agreement between the central Government, Regions and Autonomous Provinces of Trento and Bolzano regarding the New National Vaccine Plan 2005–2007. Determination 3 March 2005 in conformity with the fourth paragraph of Decree no. 281, 28 August 1997. Official Bulletin (Gazzetta Ufficiale), no. 86, 14 April 2005, Ordinary Supplement no. 63.